Here's a formal academic-style abstract inspired by the given summary and keywords:

Abstract: 
The 2023 updates to the NCCN Guidelines for metastatic breast cancer underscore the importance of integrating tumor biology and clinical factors into systemic therapy decisions. By reflecting advances in molecular profiling and targeted therapies, these guidelines provide evidence-based recommendations for managing stage IV breast cancer, thereby enhancing treatment personalization and optimizing patient outcomes.